Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2487 companies scored · 2026-10-14 run in progress: 2181 of ~5379 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-13 run
Companies scored 2487 IC ≥ 0 · market cap ≥ $100M
Median forecast +0.26% Alpha · 90D
Long–short spread +3.94% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 90D
Rating changes ▲ 48 ▼ 58 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

288 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
101 URGNUroGen Pharma Ltd. Life Sciences 0.44 $1.9B Unlock rating and forecasts
102 XNCRXencor Inc Life Sciences 0.46 $1.9B Unlock rating and forecasts
103 XERSXeris Biopharma Holdings, Inc. Life Sciences 0.21 $1.9B Unlock rating and forecasts
104 MLYSMineralys Therapeutics, Inc. Life Sciences 0.28 $1.9B Neutral +0.37% -0.30% ·
105 XTLBXTL BIOPHARMACEUTICALS LTD Life Sciences 0.15 $1.8B Neutral +0.28% +0.01% ·
106 AGIOAGIOS PHARMACEUTICALS, INC. Life Sciences 0.02 $1.8B Neutral -0.10% +0.01% ·
107 VIRVir Biotechnology, Inc. Life Sciences 0.54 $1.8B Unlock rating and forecasts
108 TRVITrevi Therapeutics, Inc. Life Sciences 0.31 $1.8B Neutral +0.23% +0.46% ·
109 SRPTSarepta Therapeutics, Inc. Life Sciences 0.25 $1.7B Unlock rating and forecasts
110 ZBIOZenas BioPharma, Inc. Life Sciences 0.19 $1.7B Unlock rating and forecasts
111 SEPNSepterna, Inc. Life Sciences 0.10 $1.7B Unlock rating and forecasts
112 MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. Life Sciences 0.62 $1.7B Unlock rating and forecasts
113 NTLAIntellia Therapeutics, Inc. Life Sciences 0.48 $1.7B Unlock rating and forecasts
114 NUVBNuvation Bio Inc. Life Sciences 0.35 $1.7B Neutral +0.37% +0.46% ·
115 ANIPANI PHARMACEUTICALS INC Life Sciences 0.46 $1.6B Unlock rating and forecasts
116 OCULOCULAR THERAPEUTIX, INC Life Sciences 0.15 $1.6B Neutral +0.81% -0.45% ·
117 GENBGenerate Biomedicines, Inc. Life Sciences 0.10 $1.6B Unlock rating and forecasts
118 CMPSCOMPASS Pathways plc Life Sciences 0.14 $1.5B Unlock rating and forecasts
119 ETONEton Pharmaceuticals, Inc. Life Sciences 0.13 $1.5B Unlock rating and forecasts
120 INVAInnoviva, Inc. Life Sciences 0.42 $1.5B Unlock rating and forecasts
121 PAHCPHIBRO ANIMAL HEALTH CORP Life Sciences 0.47 $1.5B Neutral -0.11% -0.13% ·
122 MAZEMaze Therapeutics, Inc. Life Sciences 0.30 $1.5B Unlock rating and forecasts
123 RAREUltragenyx Pharmaceutical Inc. Life Sciences 0.36 $1.5B Unlock rating and forecasts
124 STOKStoke Therapeutics, Inc. Life Sciences 0.39 $1.5B Unlock rating and forecasts
125 PCRXPacira BioSciences, Inc. Life Sciences 0.31 $1.4B Neutral +0.23% -0.06% ·
126 CBIOGYRE THERAPEUTICS, INC. Life Sciences 0.12 $1.4B Unlock rating and forecasts
127 IMCRImmunocore Holdings plc Life Sciences 0.12 $1.4B Unlock rating and forecasts
128 RAPPRapport Therapeutics, Inc. Life Sciences 0.14 $1.4B Unlock rating and forecasts
129 OMEROMEROS CORP Life Sciences 0.46 $1.4B Neutral -0.10% +0.26% ·
130 QUREuniQure N.V. Life Sciences 0.37 $1.3B Neutral +0.23% -0.04% ·
131 ANABANAPTYSBIO, INC Life Sciences 0.56 $1.3B Neutral -0.05% +0.33% ·
132 NKTRNEKTAR THERAPEUTICS Life Sciences 0.35 $1.3B Unlock rating and forecasts
133 SNDXSyndax Pharmaceuticals Inc Life Sciences 0.00 $1.2B Unlock rating and forecasts
134 GHRSGH Research PLC Life Sciences 0.05 $1.2B Unlock rating and forecasts
135 TSHATaysha Gene Therapies, Inc. Life Sciences 0.19 $1.2B Unlock rating and forecasts
136 REPLReplimune Group, Inc. Life Sciences 0.37 $1.1B Unlock rating and forecasts
137 AMPHAmphastar Pharmaceuticals, Inc. Life Sciences 0.47 $1.1B Neutral -0.11% -0.02% ·
138 TYRATyra Biosciences, Inc. Life Sciences 0.23 $1.1B Unlock rating and forecasts
139 OPKOPKO HEALTH, INC. Life Sciences 0.01 $985M Unlock rating and forecasts
140 MNKDMANNKIND CORP Life Sciences 0.57 $981M Unlock rating and forecasts
141 QDELQuidelOrtho Corp Life Sciences 0.20 $967M Neutral -0.10% +0.05% ·
142 MGTXMeiraGTx Holdings plc Life Sciences 0.10 $955M Neutral +0.18% -0.46% ·
143 IMTXImmatics N.V. Life Sciences 0.26 $916M Neutral +0.38% +0.35% ·
144 CGEMCullinan Therapeutics, Inc. Life Sciences 0.50 $907M Unlock rating and forecasts
145 RIGLRIGEL PHARMACEUTICALS INC Life Sciences 0.20 $881M Unlock rating and forecasts
146 ANROAlto Neuroscience, Inc. Life Sciences 0.19 $867M Unlock rating and forecasts
147 CYRXCryoport, Inc. Life Sciences 0.39 $858M Unlock rating and forecasts
148 ALMSALUMIS INC. Life Sciences 0.49 $849M Unlock rating and forecasts
149 GLUEMonte Rosa Therapeutics, Inc. Life Sciences 0.23 $844M Unlock rating and forecasts
150 ABUSArbutus Biopharma Corp Life Sciences 0.03 $813M Neutral +0.16% +0.14% ·
101–150 of 288 Previous Next
Since the previous run

Rating changes

▲ 48▼ 58
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.